|
gptkbp:instanceOf
|
gptkb:drug
pharmaceutical brand name
|
|
gptkbp:activeIngredient
|
gptkb:regadenoson
|
|
gptkbp:administeredBy
|
bolus injection
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:ATCCode
|
C01EB21
|
|
gptkbp:CASNumber
|
313348-27-5
|
|
gptkbp:chemicalFormula
|
C15H14N8O5
|
|
gptkbp:contraindication
|
second- or third-degree AV block without pacemaker
sinus node dysfunction without pacemaker
|
|
gptkbp:duration
|
short
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:halfLife
|
2-4 minutes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lexiscan
|
|
gptkbp:indication
|
pharmacologic stress agent
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Astellas_Pharma
|
|
gptkbp:mechanismOfAction
|
adenosine A2A receptor agonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB06213
6918537
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
dizziness
headache
flushing
dyspnea
chest discomfort
|
|
gptkbp:UNII
|
K72T3FS567
|
|
gptkbp:usedFor
|
myocardial perfusion imaging
|
|
gptkbp:usedIn
|
cardiac stress testing
|
|
gptkbp:bfsParent
|
gptkb:CV_Therapeutics
|
|
gptkbp:bfsLayer
|
6
|